Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. We all want a treatment for lung cancer that is completely safe and entirely effective. While researchers are working toward that goal, the reality is we aren’t there yet. Every treatment we are considering comes with potential benefits and side effects. The overarching role of clinical trials is to measure the pros and cons of each drug to help us identify the best treatments for

Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks. Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do. According to the National Cancer Institute, a clinical trial is a type of research study that tests how well new medical approaches (such as screening tests, prevention habits, or disease treatments) work in people. Sometimes, a clinical trial is called a clinical

Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell lung cancer (NSCLC). A lot is known about how to treat HER2 in breast cancer, and researchers are leveraging that knowledge to bring treatment options to people living with HER2-positive NSCLC. In the video below, Dr. Ibiayi Dagogo-Jack, assistant professor of Medicine at Harvard Medical School and thoracic oncologist at Massachusetts General Hospital, talks with LUNGevity’s Dr. Amy Moore about some of the frequently asked questions by

Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for free, or view the conference agenda. Last year’s conference was one of our most successful events yet, with over 900

Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist presentations and discussions, this video focuses on patient-centric endpoints, showcases this collaboration from the

On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK-positive solid tumors who have either had their disease recur or who don’t have alternative treatment options. This treatment is part of a growing trend of tissue-agnostic drugs—treatments that are prescribed based on the biomarkers found in the tumor rather than the organ where the cancer originated.   It is available to patients through the FDA’s accelerated approval process, which hurries exciting treatments to patients who need them

Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of the Integrative Medicine Center at MD Anderson Cancer Center, explains how integrative medicine can be safely

This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her expertise provides essential understanding for anyone interested in the complexities of lung cancer

On April 5, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of fam-trastuzumab deruxtecan-nxki (Enhertu®) to treat patients with unresectable or metastatic HER2-positive solid tumors. This treatment is part of a growing trend of tissue-agnostic drugs -- treatments that are prescribed based on the biomarkers found in the tumor rather than the organ where the cancer originated. It is available to patients through the FDA’s accelerated approval process, which hurries exciting treatments to patients who need them. Accelerated approvals can be controversial

In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient. These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements. Each year, LUNGevity offers a free virtual conference, the International Lung Cancer Survivorship Conference, or ILCSC, to